TEVA-TECNAL C 1/2 40 MG
CAFFEINE : 40 MG CODEINE PHOSPHATE : 30 MG ACETYLSALICYLIC ACID : 330 MG BUTALBITAL : 50 MG · DIN 00608181 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-TECNAL C 1/2?
TEVA-TECNAL C 1/2 40 MG contains CAFFEINE : 40 MG CODEINE PHOSPHATE : 30 MG ACETYLSALICYLIC ACID : 330 MG BUTALBITAL : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00608181, held by TEVA CANADA LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Nov-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-TECNAL C 1/2 used for?
Indicated for the relief of tension-type headache in adults. Not recommended for multiple recurrent headaches due to risk of medication overuse headache and addiction.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00608181 |
|---|---|
| Brand name | TEVA-TECNAL C 1/2 |
| Generic / active ingredient | CAFFEINE : 40 MG CODEINE PHOSPHATE : 30 MG ACETYLSALICYLIC ACID : 330 MG BUTALBITAL : 50 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 40 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA79 CODEIN, COMBINATIONS WITH PSYCHOLEPTICS |
| AHFS class | 28:08.08 ; 28:08.04.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Nov-2017 |
| Original market date | 1984-12-31 00:00:00 |
How is it administered?
Capsules must be swallowed whole; not to be chewed or crushed. Dosage should be individualized, starting at the low end for elderly patients. Use the lowest effective dose for the shortest duration.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store securely to avoid theft or misuse. (Specific temperature range not provided in the excerpt).
How is it supplied?
Not explicitly detailed in the provided text (section referenced but content not shown), though mentioned as capsules.
Contraindications
Hypersensitivity to ASA, caffeine, codeine, or butalbital; GI obstruction; asthma; respiratory depression; head injury; pregnancy/breast-feeding; children <18 for tonsillectomy; CYP2D6 ultra-rapid metabolizers.
Warnings and precautions
Serious risk of addiction, abuse, misuse, and fatal overdose. Life-threatening respiratory depression. Risk of death in CYP2D6 ultra-rapid metabolizers. Contains ASA (bleeding risk).
What can be used instead?
Other Canadian products sharing ATC code N02AA79 CODEIN, COMBINATIONS WITH PSYCHOLEPTICS. 6 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/2 | 50 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02554623 |
| APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/4 | 15 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02554615 |
| FIORINAL-C 1/2 | 330 MG | CAPSULE | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 00176206 |
| FIORINAL-C 1/4 | 40 MG | CAPSULE | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 00176192 |
| TEVA-TECNAL C 1/4 | 40 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00608203 |
| PHENAPHEN NO 2 CAP | 16.2 MG | CAPSULE | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01909290 |
| PHENAPHEN NO 3 CAP | 16.2 MG | CAPSULE | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01909312 |
| PHENAPHEN NO 4 CAP | 64.8 MG | CAPSULE | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01909304 |
| PHENAPHEN NO.2 CAP | 16.2 MG | CAPSULE | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | DIN 02042851 |
| PHENAPHEN NO.3 CAP | 325 MG | CAPSULE | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | DIN 02042878 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.